An X - Search Results

1

A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology.

Xu X, Kumari R, Zhou J, Chen J, Mao B, Wang J, Zheng M, Tu X, An X, Chen X, Zhang L, Tian X, Wang H, Dong X, Bao Z, Guo S, Ouyang X, Shang L, Wang F, Yan X, Zhang R, Vries RGJ, Clevers H, Li QX. Xu X, et al. Among authors: an x. PLoS One. 2023 Jan 5;18(1):e0279821. doi: 10.1371/journal.pone.0279821. eCollection 2023. PLoS One. 2023. PMID: 36602988 Free PMC article.

2

AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.

An X, Liu J, Wang N, Wang D, Huang L, Zhang L, Cai J, Wery JP, Zhou D, Zhou J, Li QX. An X, et al. Exp Hematol. 2017 Jan;45:36-44.e2. doi: 10.1016/j.exphem.2016.09.004. Epub 2016 Sep 23. Exp Hematol. 2017. PMID: 27670587 Free article.

3

Experimental animal modeling for immuno-oncology.

Li QX, Feuer G, Ouyang X, An X. Li QX, et al. Among authors: an x. Pharmacol Ther. 2017 May;173:34-46. doi: 10.1016/j.pharmthera.2017.02.002. Epub 2017 Feb 4. Pharmacol Ther. 2017. PMID: 28167217 Review.

4

Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry.

An X, Ouyang X, Zhang H, Li T, Huang YY, Li Z, Zhou D, Li QX. An X, et al. J Vis Exp. 2018 Oct 9;(140):57460. doi: 10.3791/57460. J Vis Exp. 2018. PMID: 30371656 Free PMC article.

5

In Vivo Pharmacology Models for Cancer Target Research.

Chen D, An X, Ouyang X, Cai J, Zhou D, Li QX. Chen D, et al. Among authors: an x. Methods Mol Biol. 2019;1953:183-211. doi: 10.1007/978-1-4939-9145-7_12. Methods Mol Biol. 2019. PMID: 30912023

6

Corrigendum to "AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes" [Experimental Hematology 2017;45:36-44].

An X, Liu J, Wang N, Wang D, Huang L, Zhang L, Cai J, Wery JP, Zhou D, Zhou J, Li QX. An X, et al. Exp Hematol. 2021 Jan;93:85. doi: 10.1016/j.exphem.2020.10.004. Epub 2020 Nov 12. Exp Hematol. 2021. PMID: 33189657 Free article. No abstract available.

7

Preclinical pharmacology modeling of chimeric antigen receptor T therapies.

Kumari R, Ouyang X, Wang J, Xu X, Zheng M, An X, Li QX. Kumari R, et al. Among authors: an x. Curr Opin Pharmacol. 2021 Dec;61:49-61. doi: 10.1016/j.coph.2021.08.008. Epub 2021 Oct 5. Curr Opin Pharmacol. 2021. PMID: 34619442 Review.

8

Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.

Jin Y, An X, Mao B, Sun R, Kumari R, Chen X, Shan Y, Zang M, Xu L, Muntel J, Beeler K, Bruderer R, Reiter L, Guo S, Zhou D, Li QX, Ouyang X. Jin Y, et al. Among authors: an x. Sci Rep. 2022 Feb 28;12(1):3278. doi: 10.1038/s41598-022-07153-z. Sci Rep. 2022. PMID: 35228603 Free PMC article.

9

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.

Ke H, Zhang F, Wang J, Xiong L, An X, Tu X, Chen C, Wang Y, Mao B, Guo S, Ju C, He X, Sun R, Zhang L, O'Connor OA, Li QX. Ke H, et al. Among authors: an x. Sci Rep. 2023 Apr 3;13(1):5419. doi: 10.1038/s41598-023-32547-y. Sci Rep. 2023. PMID: 37012357 Free PMC article.

10

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.

Yang T, Ke H, Liu J, An X, Xue J, Ning J, Hao F, Xiong L, Chen C, Wang Y, Zheng J, Gao B, Bao Z, Gong K, Zhang L, Zhang F, Guo S, Li QX. Yang T, et al. Among authors: an x. Sci Rep. 2024 Apr 19;14(1):9032. doi: 10.1038/s41598-024-59650-y. Sci Rep. 2024. PMID: 38641704 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,779 results

Search Page